Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib in RET-Altered Advanced Solid Tumors and Medullary Thyroid Cancer
NCT04280081Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selpercatinib in solid tumor and Medullary Thyroid Cancer (MTC), sponsored by Eli Lilly and Company. Primary endpoint: Overall Response Rate up to 12 months. Started Mar 2020; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
solid tumorMedullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT04280081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280081.